Skip to content
OpenCapital
Get started

Amphastar Pharmaceuticals AMPH Q4 2025 Annual earnings

Reported February 26, 2026 · After market close

Revenue$183.1MMiss by $5.7M
EPS$0.73Miss by $0.17
Revenue estimate$188.8M
EPS estimate$0.90

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$179.9M
EPS estimate$0.66

Financials

Q4 2025

Income statement

See full
Revenue$183.1M-1.8%
Gross profit$85.7M-1.1%
Operating income$35.6M-21.1%
Net income$24.4M-35.7%
EPS (diluted)$0.51-31.1%

Balance sheet

See full
Cash & equivalents$170.2M+12.2%
Total debt$656.3M+0.8%
Total assets$1.6B+3.3%

Cash flow

See full
Operating cash flow$32.9M+13.2%
CapEx$8.3M-33.3%
Free cash flow$24.6M+48.0%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.23B-31.1%
Enterprise value$1.72B-24.9%
P/E12.5×+1.4×
P/S1.7×-0.7×

Profitability

See full
Gross margin49.5%-1.6pp
Operating margin19.5%-8.6pp
Net margin13.6%-8.2pp
FCF margin16.8%-6.7pp

Returns & leverage

See full
Current ratio4×+0.9×

Segments

By geography

See full
US$171.6M-2.0%
FR$10.6M+15.0%
CN$925.0K-57.8%

Versus estimates

Revenue

Q1 2026$171.2MMiss by $2.3M
Q4 2025$183.1MMiss by $5.7M
Q3 2025$191.8MBeat by $1.4MQ2 2025$174.4MMiss by $2.7MQ1 2025$170.5MMiss by $2.5MQ4 2024$186.5MMiss by $2.3M

Diluted EPS

Q1 2026$0.42Miss by $0.28
Q4 2025$0.73Miss by $0.17
Q3 2025$0.93Beat by $0.16Q2 2025$0.85Beat by $0.14Q1 2025$0.74Beat by $0.08Q4 2024$0.92Miss by $0.09

Ask the moment Amphastar Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Amphastar Pharmaceuticals report Q4 2025 earnings?
Amphastar Pharmaceuticals (AMPH) reported Q4 2025 earnings on February 26, 2026 after market close.
What were Amphastar Pharmaceuticals's Q4 2025 revenue and EPS?
Amphastar Pharmaceuticals reported revenue of $183.1M and eps of $0.73 for Q4 2025.
Did Amphastar Pharmaceuticals beat estimates in Q4 2025?
Revenue missed the consensus estimate of $188.8M by $5.7M. EPS missed the consensus estimate of $0.90 by $0.17.
How did Amphastar Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 1.8% from $186.5M a year earlier and eps declined 20.7% from $0.92.
Where can I find Amphastar Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001297184-26-000007) and the 10-K periodic report (0001297184-26-000009) directly on SEC EDGAR. The filing index links above go to sec.gov.